| Montgomery, Robert B |
| Active, not recruiting | 3 | 1100 | Europe, Canada, US, RoW | Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy | University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium | Prostate Cancer | 01/28 | 07/28 | | |
| Recruiting | 2 | 100 | US | Carboplatin, Paraplatin, Olaparib, Lynparza | VA Office of Research and Development | Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations | 08/25 | 08/25 | | |
| Recruiting | 2 | 51 | US | High dose testosterone, Bipolar androgen therapy | VA Office of Research and Development | Metastatic Prostate Cancer | 08/26 | 08/27 | | |
SNARE, NCT05593497: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss |
|
|
| Recruiting | 2 | 30 | US | Capivasertib, abiraterone acetate | VA Office of Research and Development | High-Risk Prostate Cancer | 05/27 | 08/27 | | |
| Recruiting | 1/2 | 30 | US | INKmune | Inmune Bio, Inc. | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 05/25 | 11/25 | | |
| Active, not recruiting | N/A | 67 | US | Oral Sodium Chloride, Placebo | The Cleveland Clinic | Volume Overload | 06/22 | 06/25 | | |
NCI-2014-01087, NCT01050504: Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer |
|
|
| Recruiting | N/A | 1500 | US | Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis | University of Washington, National Cancer Institute (NCI) | Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7 | 01/29 | 01/29 | | |
| Locke, Jayme |
NCT05340426: Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease |
|
|
| Withdrawn | 1 | 20 | US | UKidney, Porcine Kidney, Xenotransplant | University of Alabama at Birmingham, United Therapeutics, Lung Biotechnology PBC | Kidney Failure, Chronic | 06/28 | 06/29 | | |
NCT04341896: Healthcare Utilization in Obese Caregiver Living Donors |
|
|
| Completed | N/A | 784 | US | Caregivers, Non-caregivers | University of Alabama at Birmingham | Utilization, Health Care, Obesity | 03/24 | 12/24 | | |
| Enrolling by invitation | N/A | 440 | US | Living Donor Navigator Program | University of Alabama at Birmingham, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Kidney Diseases | 11/25 | 02/26 | | |
| Brennan, Daniel C |
NCT05917522: Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation |
|
|
| Recruiting | 2 | 800 | US | Abatacept, Orencia, Standard of Care at US Transplant Centers | National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Transplant | 07/27 | 07/29 | | |
NCT01309022: Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) |
|
|
| No Longer Available | N/A | | US | Sirolimus, Rapamune®, Tacrolimus, Prograf®, Mycophenolate mofetil, MMF, CellCept, Mycophenolic acid, Myfortic® | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Diabetes Mellitus, Type 1 | | | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/25 | 12/26 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry |
|
|
| Active, not recruiting | N/A | 4000 | US | Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox) | CareDx | Kidney Transplant Rejection | 06/25 | 12/25 | | |
| Ostrander, Darin |
COLT, NCT06075745: Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates |
|
|
| Recruiting | 2 | 416 | US | CMV-MVA Triplex, Placebo for CMV-MVA Triplex | National Institute of Allergy and Infectious Diseases (NIAID) | Liver Transplant | 06/27 | 02/28 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/25 | 12/26 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
| Toure, Raissa |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/25 | 12/26 | | |
